Community curated by people like you

Weight loss stories

Apr 13, 2026

Genetic Variants Explain Why GLP-1 Drugs Like Ozempic Don't Work for 10% of Patients

New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.

Apr 13, 2026·1 source

00

Top claims

▪Experiments with collaborators in Copenhagen showed that the PAM defect does not affect how GLP-1 binds to its receptor or how signals are transmitted
▪Two additional clinical trials funded by pharmaceutical companies showed no difference in response between PAM variant carriers and non-carriers when using longer-acting GLP-1 drugs
▪In a combined analysis of three clinical trials with 1,119 participants, individuals with PAM variants responded less effectively to GLP-1 drugs and were less likely to reach target HbA1c levels

Topics

Supplementation fundamentals Drug Approval and Clinical Trials Metabolic health Lifestyle, Wellness and Nutrition GLP-1 medications Biomarkers & bloodwork testing Nutrition fundamentals Blood sugar & insulin

Related entities

Ozempic Genetic